Comparing two new cell therapies for aggressive lymphoma that didn't respond to initial treatment

Plain-English translation of NCT07479797 on ClinicalTrials.gov ↗ · Source last updated June 2026 · Translation generated June 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This trial is testing whether a newer cell therapy called works better than an existing cell therapy () for people with aggressive B-cell lymphoma that either came back after initial treatment or didn't respond to it in the first place. Both treatments work by taking your own immune cells, training them in a lab to recognize and fight cancer cells, and putting them back into your body. The study wants to see which one helps more people get better.

When aggressive B-cell lymphoma doesn't respond to standard chemotherapy or comes back shortly after treatment, patients need new options. This medication represents a promising approach, but researchers need to find out whether this newer version is an improvement over the existing cell therapy option.

Do you qualify?

You likely qualify if…

you have been diagnosed with aggressive B-cell lymphoma (large B-cell lymphoma) that either didn't respond to your first chemotherapy treatment or came back within 12 months of finishing it
your first-line treatment included both an anti-CD20 antibody drug and chemotherapy containing an anthracycline
you have at least one tumor that can be measured on imaging scans
it has been at least 2 weeks since your last cancer treatment (or 5 half-lives of the drug, whichever is shorter)
any side effects from your previous treatments have improved to mild levels or resolved
you are in reasonably good overall health (ECOG performance status of 2 or better) and have adequate bone marrow function

You likely don't qualify if…

you have received more than one line of chemotherapy for your lymphoma
you have had any other systemic cancer treatment between your first-line therapy and enrolling in the study (except steroids or local radiation)
you have severe organ damage or other serious medical conditions that would make the treatment unsafe
you are currently taking certain medications that would interfere with this therapy

What participation looks like

You will receive chemotherapy ( and ) to prepare your body, followed by a single infusion of the study medication — your own immune cells that have been trained to fight the cancer. Before treatment starts, your blood will be collected to harvest these immune cells, which will be sent to a lab for processing. You'll be closely monitored during and after the infusion for side effects, with regular clinic visits and scans to track how well the treatment is working.

AI-generated summary from trial data · Jun 24, 2026 · Not medical advice

Trial locations(2 sites)

United States

Stanford University, Stanford, California

Australia

Epworth Healthcare, East Melbourne, Victoria